Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis

Abstract Prevalence of non-alcoholic steatohepatitis (NASH) rises steadily in Western countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposes to cirrhosis and associated morbi-mortality. The cannabinoid system is increasingly emerging as a crucia...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes & metabolism 2008-12, Vol.34 (6), p.680-684
Main Authors: Mallat, A, Lotersztajn, S
Format: Article
Language:English
Subjects:
Arachidonic Acids
Arachidonic Acids - therapeutic use
Biochemistry, Molecular Biology
Biological and medical sciences
Cannabinoid receptors
Cannabinoids
Cannabinoids - therapeutic use
Diabetes. Impaired glucose tolerance
Endocannabinoids
Endocannabinoïdes
Endocrine pancreas. Apud cells (diseases)
Endocrinology & Metabolism
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Fatty Liver
Fatty Liver - drug therapy
Fatty Liver - physiopathology
Fatty Liver - prevention & control
Fibrose hépatique
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Insulin Resistance
Insulin Resistance - physiology
Internal Medicine
Life Sciences
Liver fibrosis
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Non-alcoholic steatohepatitis
Other diseases. Semiology
Polyunsaturated Alkamides
Polyunsaturated Alkamides - therapeutic use
Receptor, Cannabinoid, CB1
Receptor, Cannabinoid, CB1 - drug effects
Receptor, Cannabinoid, CB1 - physiology
Receptor, Cannabinoid, CB2
Receptor, Cannabinoid, CB2 - drug effects
Receptor, Cannabinoid, CB2 - physiology
Receptors, Cannabinoid
Receptors, Cannabinoid - drug effects
Review
Revue générale
Récepteurs des cannabinoïdes
Stéatohépatite non alcoolique
Stéatose
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Prevalence of non-alcoholic steatohepatitis (NASH) rises steadily in Western countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposes to cirrhosis and associated morbi-mortality. The cannabinoid system is increasingly emerging as a crucial mediator of acute and chronic liver injury. Recent experimental and clinical data indicate that peripheral activation of cannabinoid CB1 receptors promotes insulin resistance and liver steatogenesis, two key steps in the pathogenesis of non-alcoholic fatty liver disease. Moreover, CB1 receptors enhance progression of liver fibrogenesis. These findings provide a strong rationale for the use of CB1 antagonists in the management of NASH.
ISSN:1262-3636
1878-1780
DOI:10.1016/S1262-3636(08)74604-4